CEJEMLY

This brand name is authorized in Lithuania

Active ingredients

The drug CEJEMLY contains one active pharmaceutical ingredient (API):

1 Sugemalimab
UNII 90IQR2I6TR - SUGEMALIMAB

Sugemalimab is a fully human immunoglobulin G4 monoclonal antibody. It specifically binds to programmed cell death ligand 1 (PD-L1), thus blocking its ligation with PD-1.

Read about Sugemalimab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
CEJEMLY Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01FF11 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: LT Valstybinฤ— vaistลณ kontrolฤ—s tarnyba Identifier(s): 1100765

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈